Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 6, 2011

View Archived Issues

Promising findings made available from dal-VESSEL trial

Data disclosed from ARISTOTLE trial of apixaban vs. warfarin in atrial fibrillation

Daiichi Sankyo identifies new pyrrolobenzoxazepine derivatives

Eisai divulges additional phase III data on proprietary AMPA-type glutamate receptor antagonist

Lu-AA-21004 prevents relapse of major depression in long-term trial

Methylene blue beneficial as adjunctive therapy for bipolar disorder

New progesterone receptor antagonists claimed

New peroxisome proliferator-activated receptor-gamma agonists presented

Novel sanglifehrin analogues reported

Shionogi & Co. claims new neuropeptide Y5 receptor antagonists

Astellas Pharma and Evec sign license agreement

NCI recruits patients for phase II trial of sipuleucel-T

Hybrigenics receives approval and funding for phase II inecalcitol trial in France

Promising results reported from phase II SAPHIRE trial

Inhibitex initiates phase II study of INX-08189

AMT and NIH sign exclusive license agreement for AAV-5-based gene therapy vectors

Noxxon Pharma begins first-in-human trial of NOX-H94

Evotec and Roche enter worldwide agreement for EVT-302

GeoVax Labs' HIV/AIDS vaccine development program receives NIAID grant boost

FDA expands indication of Baxter's Artiss

Randomized phase II trial to evaluate LY-2523355 in metastatic breast cancer

FDA issues warning regarding 5-alpha reductase inhibitors

Pharmasset releases SVR12 results from phase IIb study of PSI-7977

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Hippocratic loath? ‘Harm’ threat from ACIP’s proposed HBV shift
BioWorld
Individual liberty and choice vs. wider public health became one predictable hinge upon which swung the often-acerbic debates at the CDC’s Advisory Committee for...
Høeg appointment as acting CDER director tied to vaccine strategy?
BioWorld
After a more than 13-year period of stability with Janet Woodcock as the head of CDER, with Patrizia Cavazzoni taking charge during the next four years of former...
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...